


The Federal Circuit Strikes Again in Enzo-Biochem

THE LATEST ON THE WRITTEN DESCRIPTION REQUIREMENT FOR VALID BIOTECH PATENTS



BY HOWARD LESLIE HOFFENBERG, ESQ.

Howard Hoffenberg is the principle of the Law Offices of Howard Hoffenberg (Los Angeles, California 310-670-

5825) and is Of Counsel at Park & Sutton, LLP. (Los Angeles, California 213-389-3777.) He holds a J.D. (1985) from DePaul University (Chicago) and a B.S. (1982) in Biochemistry and Chemistry from the University of Illinois. He is a member of the state bars for California, Illinois and New York and a registered patent attorney. Mr. Hoffenberg is a member of the American Chemical Society. He volunteers as a temporary judge in the Superior Court and as a Settlement Officer in the Court of Appeals. Mr. Hoffenberg's practice focuses on business transactions, intellectual property and dispute resolution.

On April 2, 2002, the Federal Circuit issued a major decision on the written description requirement (35 U.S.C. § 112, ¶ 1) for biotech patents (see, Enzo-Biochem v. Gen-Probe, ___ F.3d ___, 2002 WL 487156 (Fed. Cir. 2002.)) In this decision, the Federal Circuit commented upon the PTO's new Guidelines for Examination of Patent Applications Under 35 U.S.C. 112, ¶ 1, 66 Fed. Reg. 1,099 (Jan. 5, 2001) ("Guidelines").

In a "nutshell," the facts of the case are as follows. Enzo-Biochem developed three nucleic acid probes that selectively hybridized to DNA in *N. gonorrhoeae*. The probes were deposited for public availability with the American Type Culture Collection. In seeking patent protection for the probes, the patent specification described the probes by their property of binding to *N. gonorrhoeae* in a preferential

ratio of "greater than about five" with respect to *N. meningitidis*. The specification also included "vague details" regarding how the probes were obtained and an approximate length of the probes. The nucleotide sequence of the hybridization site on the genomic DNA of *N. gonorrhoeae* was not described.

The district court declared the patent invalid for failure to satisfy the written description requirement. The Federal Circuit affirmed with a published memorandum decision. This decision provides the following practice pointers:

PRACTICE POINTER NO. 1

The Court reiterated its general proposition of law from University of California v. Eli Lilly & Co., 119 F.3d 1559 (Fed. Cir. 1997), that an "adequate written description of genetic material requires a precise definition, such as by structure, formula, chemical name, or physical properties, ... The disclosure must allow one skilled in the art to visualize or recognize the identity of the subject matter of the claim ... A description of what the genetic material does, rather than of what it is, does not suffice" (Note, see Practice Pointer 3, infra.)

PRACTICE POINTER NO. 2

Specifying a selective binding affinity (i.e., a function) does not provide an adequate written description where it is the only characteristic describing the claimed nucleotide sequence. The Court rejected "Enzo's characterization of hybridization as a distinctive 'chemical property' of the claimed sequences." The Court opined that "[d]escribing a complicated molecule by means of a broad generic term (a nucleotide sequence) plus its function fails to distinguish it from molecules that can perform the same function" (Note, see Practice Pointer 3, infra.)

PRACTICE POINTER NO. 3

The Court left open the possibility that a functional description could serve as an adequate description under circumstances where "the claimed function is known to correlate to a specific structure or other

identifying characteristic that is disclosed or otherwise well known."

The Court made the following statement which infers that a description based on ability to hybridize would be an adequate description where there is sequence information on the hybridization site:

"Thus, in the absence of sequence information for its hybridization site, a nucleic acid described only by its ability to hybridize with another DNA fails to meet the requirements of §112, ¶ 1."

The Court discussed with apparent approval the illustration in the Guidelines of a monoclonal antibody binding to antigen X as being an adequate written description considering "the well defined structural characteristics ... of antibody the functional characteristics of antibody binding, and ... the technology is well developed and mature."

PRACTICE POINTER NO. 4

The Court rejected that making a deposit provides an adequate written description. In so holding, the Court was unpersuaded by the argument that the genetic material in the deposit could be sequenced. The Court explained that deposits are not part of the specification and their purpose is to satisfy enablement requirements. The specification itself must provide a description "sufficient to aid the resolution of issues of infringement and "adequate ... for proper examination of the application."

PRACTICE POINTER NO. 5

The Court clarified that the written description requirement is not necessarily satisfied where the claimed subject matter is described in the patent specification *ipsis verbis* (i.e., the claim language copied over verbatim, or near verbatim, in the specification.) This is known as "Original Claim Doctrine." The Court stated that if a purported description does not meet the requirements of the statute, the fact that it appears as an original claim does not save it. The Original Claim Doctrine is useful where the issue is showing possession of the claimed subject matter; e.g., when seeking priority from an earlier filed application, adding new claims during prosecution or meeting a claim in interference. **IPT**